Opdivo Lung Cancer Approval Exceeds Rosiest Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
Even given huge optimism to date for immunotherapy checkpoint inhibitors, the rapid approval of Bristol’s PD-1 inhibitor nivolumab in squamous type lung cancer is a welcome surprise and bodes well for the class in the future.